Bio News
Novartis’ radioligand therapy Pluvicto has received FDA approval as an early-stage treatment for metastatic castration-sensitive prostate cancer (mHSPC), nearly doubling the eligible patient population. When used in combination with standard therapy, the drug was found to reduce the risk of disease progression and death by 33%. With the approval, Novartis is expected to accelerate efforts to achieve annual sales of up to $5 billion (approximately 7.5 trillion won).
Biobook Team
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
